AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (1.1 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

CDK9 inhibitor elicits APC through a synthetic lethal effect in colorectal cancer cells

Tingming Lianga, Lulu Luoa, Xinru Xua, Yajing Dua, Xinbing Yanga, Jiahui Xiaoa, Xiaoyan Huanga, Huiying Yanga, Siyu Wanga, Li Guob( )
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing, Jiangsu 210023, China
State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, Jiangsu 210023, China

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Genes & Diseases
Volume 12 Issue 1,
January 2025
Article number: 101220
DOI: 10.1016/j.gendis.2024.101220

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Liang T, Luo L, Xu X, et al. CDK9 inhibitor elicits APC through a synthetic lethal effect in colorectal cancer cells. Genes & Diseases, 2025, 12(1): 101220. https://doi.org/10.1016/j.gendis.2024.101220

685

Views

25

Downloads

2

Crossref

2

Web of Science

2

Scopus

0

CSCD
Received: 09 October 2023
Published: 24 January 2024
© 2024 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).